Medications used for diabetes and weight loss have been linked to gastroparesis or stomach paralysis and other severe side effects.
Ozempic, Wegovy, Saxenda, Victoza, Mounjaro and Rybelsus, widely prescribed medication for diabetes management and weight loss, are under scrutiny as a proposed class action gains momentum. Allegations of undisclosed adverse gastric effects have surfaced, prompting users to explore their legal options.
The proposed class action against makers of these drugs revolves around the claim that users were not adequately informed about potential health risks associated with their use. Plaintiffs argue that the manufacturers failed to disclose harmful adverse gastric effects and permanent injury. The class action seeks to hold the pharmaceutical companies accountable for any damages suffered by individuals using these drugs.
Adverse Gastric Effects
Medical professionals and the U.S. Food and Drug Administration have reported increased numbers of Emergency room visits and hospitalizations related to complications caused by these medications.
Some of these complications include:
- Gastroparesis (paralysis of the stomach),
- Bowel obstruction (blocked intestine), and
- Pulmonary aspiration while under anesthesia or during surgery.
These complications, allegedly downplayed or omitted in the drug’s marketing materials, have raised concerns among healthcare professionals and users alike. Drugmakers Eli Lilly and Novo Nordisk may be facing numerous lawsuits filed by people who used the medications and experienced serious complications or required hospitalization.
Medical Community Response
The emerging evidence of adverse gastric effects associated with these drugs has prompted the medical community to reassess their safety profile. Physicians are urging caution and emphasizing the importance of transparent communication regarding potential side effects to empower patients to make informed decisions about their health.
As the class action gains traction, legal experts anticipate a thorough examination of the evidence surrounding the alleged failure of manufacturers to disclose adverse gastric effects. If successful, the class action could result in compensation for affected individuals and serve as a catalyst for increased transparency in pharmaceutical marketing practices.
Join The Ozempic Mounjaro GLP-1 Gastroparesis Lawsuit
The proposed Ozempic Mounjaro GLP-1 class action brings to light the importance of informed decision-making in healthcare. Users deserve comprehensive information about the potential risks associated with any prescribed medication. As the legal proceedings unfold, the focus on undisclosed adverse effects underscores the need for transparency, accountability, and the protection of patient well-being in the pharmaceutical industry. Stay informed, stay vigilant, and consider your options.
If you experienced serious complications or required hospitalization and/or experienced pulmonary aspiration during surgery while under anesthesia after using Ozempic, Wegovy, Saxenda, Victoza, or Mounjaro, you may be eligible for compensation. Please fill out the form below and a product liability lawyer will contact you to discuss your claim. There is no cost or obligation on your part.